MDXXF (Pharmala Biotech Holdings) EBIT: $-1.15 Mil (TTM As of Feb. 2026)


MDXXF Pharmala Biotech Holdings Inc MDXXF
35 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharmala Biotech Holdings EBIT?

Pharmala Biotech Holdings MDXXF +7.74% 35 EBIT is $-1.15 Mil as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 35/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Pharmala Biotech Holdings's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was $-0.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was $-1.15 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharmala Biotech Holdings's annualized ROC % for the quarter that ended in Feb. 2026 was -61.67%. Pharmala Biotech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -68,000.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pharmala Biotech Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -9.91%.

Pharmala Biotech Holdings  (OTCPK:MDXXF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharmala Biotech Holdings's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-1.02 * ( 1 - 0% )/( (1.647 + 1.661)/ 2 )
=-1.02/1.654
=-61.67 %

where

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.418 - 0.332 - ( 0.61 - max(0, 0.731 - 1.17+0.61))
=1.647

Invested Capital(Q: Feb. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.293 - 0.33 - ( 0.414 - max(0, 0.713 - 1.015+0.414))
=1.661

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharmala Biotech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.02/( ( (0.002 + max(-0.301, 0)) + (0.001 + max(-0.241, 0)) )/ 2 )
=-1.02/( ( 0.002 + 0.001 )/ 2 )
=-1.02/0.0015
=-68,000.00 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.138 + 0.255 + 0.037) - (0.332 + 0.398 + 0.001)
=-0.301

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.177 + 0.284 + 0.011) - (0.33 + 0.382 + 0.001)
=-0.241

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pharmala Biotech Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-1.151/11.620
=-9.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings EBIT Related Terms

Pharmala Biotech Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings EBIT Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
EBIT
-1.99 -0.76 -0.57 -0.47 -1.55

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.37 -0.28 -0.25 -0.26

MDXXF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's EV-to-EBIT falls into.


MDXXF
35GF Score
Pharmala Biotech Holdings Inc MDXXF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-1.15 Mil mean?
Pharmala Biotech Holdings (MDXXF) has a EBIT of $-1.15 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharmala Biotech Holdings.
Is Pharmala Biotech Holdings' EBIT too high?
Pharmala Biotech Holdings' current EBIT is $-1.15 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' EBIT compare to VRTX and REGN?
Pharmala Biotech Holdings' EBIT of $-1.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharmala Biotech Holdings. Pharmala Biotech Holdings's current EBIT is $-1.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current EBIT is $-1.15 Mil. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current EBIT is $-1.15 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • EBIT: $-1.15 Mil
  • GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score

Get the complete analysis for MDXXF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value